Harry W. Severance, MD, FACEP, Medical Director for the Erlanger Institute for Clinical Research, Erlanger emergency medicine physician, and Director of Clinical Research Trials at the University of Tennessee College of Medicine Chattanooga, has been selected to serve on the board of directors for the Duke University Cooperative Cardiovascular Society (DUCCS).
Dr. Severance will serve a three-year term on the DUCCS board of directors. The DUCCS is a society of current and past Duke faculty members and fellows of Duke’s cardiovascular diseases training program, along with clinical educators and investigators. The purpose of the DUCCS is to enhance collaborative efforts of its members in cardiovascular research and continuing education. DUCCS supports the scholarly interests of its members by providing research and educational programs.
“Dr. Severance’s selection to the board of this distinguished society of physicians reflects the high caliber of his clinical research and performance as an emergency physician,” said Kevin M. Spiegel, FACHE, Erlanger President and CEO. “Erlanger and the Collegeof Medicine are fortunate that he has chosen to practice and teach here in Chattanooga.”
Through his affiliation with Erlanger and the UT College of Medicine, Dr. Severance is responsible for conducting clinical research trials in all areas of Erlanger, ranging from intensive care to cardiovascular medicine. He has authored dozens of papers that have been published in national medical journals.
After receiving an undergraduate degree from Duke University, Dr. Severance received his medical degree from Duke University School of Medicine. He completed his residency training at East Carolina University.